Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Bayer licenses human use of emodepside, collaborates with DNDi

Executive Summary

Astellas Pharma Inc. licensed Bayer HealthCare Pharmaceuticals AG rights to develop the macrofilaricidal drug emodepside for onchocerciasis (river blindness), a neglected tropical disease (NTD) transmitted by blackflies, which live and breed near streams and rivers. Bayer sublicensed rights to Drugs for Neglected Disease initiative (DNDi), which will make emodepside available at the lowest sustainable price to the 31 African disease-endemic countries.
Deal Industry
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • R&D and Marketing (Licensing)

Related Companies